Preliminary results of MR imaging with superparamagnetic iron oxide in pancreatic and retroperitoneal disorders

The authors conducted a preliminary evaluation of the potential of superparamagnetic iron oxide as contrast material for delineation of the bowel. Ten patients with various pancreatic diseases and 18 patients with suspected retroperitoneal disease underwent T1- and T2-weighted MR imaging before and after contrast material was administered. Two radiologists reviewed randomized images and scored them for depiction of anatomic structures and abnormalities. In most patients, postcontrast T1-weighted images showed improved delineation of the retroperitoneal small bowel (duodenum), stomach, and pancreas. Postcontrast T2-weighted images showed improved delineation of retroperitoneal small bowel, para-aortic region, peripancreatic fat, and renal veins. There was no improvement in delineation of retroperitoneal diseases, except for lymphadenopathy, which was better seen on both T1- and T2-weighted postcontrast images. Preliminary results suggest that superparamagnetic iron oxide is a useful contrast agent for delineating some normal retroperitoneal structures, lymphadenopathy, and pancreatic disease and that it is less useful in evaluating other retroperitoneal masses.     

Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging.

OBJECTIVE: Our objective was to compare the efficacy of a positive and a negative oral contrast agent and to determine the optimal sequence choice for use in pelvic MR imaging. SUBJECTS AND METHODS: We undertook a prospective randomized trial of 57 patients with pelvic cancer who were examined with MR imaging after oral administration of a positive contrast agent (27 patients) or a negative contrast agent (30 patients). T1- and T2-weighted breath-hold and non-breath-hold gradient-recalled echo and turbo spin-echo sequences were obtained. Using the hard-copy images, we graded filling and distention of the small bowel, bowel wall conspicuity, delineation of normal and pathologic structures, and artifacts. RESULTS: Good or excellent small-bowel filling and distention was obtained in 17 patients (63%) receiving the positive agent and in 26 patients (87%) receiving the negative agent, and bowel wall conspicuity was graded good or excellent in 19 patients (70%) and 20 patients (67%), respectively. Normal and pathologic structures were better delineated with the negative agent (20 patients [74%] and 27 patients [90%], respectively; p = .02). Breath-hold gradient-recalled echo T1-weighted images were preferred for the positive agent (78%), and breath-hold T2-weighted images were preferred for the negative agent (93%). Contrast artifacts were more frequently seen with the negative agent (11% and 93%, respectively; p = .0001), and such artifacts were eliminated using T2-weighted sequences. CONCLUSION: Both contrast agents were effective in pelvic MR imaging, but delineation of normal and pathologic structures was better with the negative agent. Gradient-recalled echo T1-weighted sequences are recommended for positive contrast agents, and breath-hold T2-weighted sequences are recommended for negative contrast agents.     

Rectal barium in pelvic MR imaging: initial results.

Pelvic magnetic resonance (MR) imaging is limited by lack of an effective bowel contrast agent. This study was performed to evaluate the efficacy of rectally administered barium sulfate as a contrast agent in pelvic MR imaging. Thirty-two patients were studied retrospectively to evaluate anatomic definition of the rectosigmoid colon. A commercially available barium sulfate suspension was administered rectally in 19 patients. Thirteen patients were imaged without barium. In the latter patients, anatomic definition of the rectum and sigmoid colon was poor to fair with all pulse sequences. Delineation of the rectum and sigmoid colon improved in patients who received rectal barium, owing to distention and marking of the bowel by the predominantly low-signal-intensity barium. Barium is a safe, inexpensive negative contrast agent for bowel that may improve pelvic MR imaging.     

Comparison of MR imaging after barium administration with CT in pelvic disease.

The use of magnetic resonance (MR) imaging for evaluating the abdomen and pelvis has been limited by the lack of a suitable contrast agent. The purpose of this study was to compare axial MR imaging after rectal barium administration with computed tomography (CT) for delineation of normal anatomy and lesions of the pelvis. MR images and CT scans of 11 patients were studied retrospectively and independently by four radiologists. No substantial differences in the visualization of normal bowel, iliac vessels, lymph nodes, bladder, prostate, seminal vesicles, uterus, and cervix and in detection of abnormalities were seen between CT scans and axial MR images obtained after barium administration. This preliminary study suggests that axial MR imaging with rectal barium is a useful alternative to CT in evaluating pelvic disease.     

Use of nutritional support formula as a gastrointestinal contrast agent for MRI.

The objective of this study was to evaluate the potential utility of a nutritional support formula to serve as a practical means of enhancing the gastrointestinal tract on abdominal MR images. Nutritional support formula (Ensure Plus) was administered to 29 patients prior to abdominal MRI. Standard T1-weighted and T2-weighted pulse sequences were performed, in addition to fat suppression and inversion recovery sequences in selected patients. Images in these patients were evaluated for degree and uniformity of gastrointestinal tract enhancement and delineation of the bowel wall and pancreas. Results were compared with those obtained in 10 control patients. Marked enhancement of gastric contents was present in nearly all patients who received nutritional support formula on both T1-weighted and T2-weighted sequences, with mild to moderate enhancement of small bowel and colon in most patients. Although gastrointestinal and respiratory motion artifacts often limited bowel wall delineation, excellent delineation of the gastric wall and pancreas was provided. Phantom experiments demonstrated that gastrointestinal tract enhancement with nutritional support formula is due to the paramagnetic trace elements, corn syrup, and lipid material it contains. Such a formula requires no preparation, is safe, inexpensive, palatable, readily available, and represents a practical means of enhancing the gastrointestinal tract on MRI.     

Evaluation of potential gastrointestinal contrast agents for echoplanar MR imaging

Although the diagnostic application of echoplanar imaging (EPI) has until now been limited, recent technical advances provide anatomic resolution and signal-to-noise ratios comparable to that of conventional MR imaging. The purpose of this study was to investigate approved aqueous gastrointestinal contrast agents for use in abdominal EPI. Conventional and echoplanar MR imaging experiments were performed with 1.0 Tesla whole body systems. Phantom measurements of Gastrografin, barium sulfate suspension, oral gadopentetate dimeglumine, water, and saline were performed. Signal intensity (SI) of aqueous oral barium sulfate and iodine based CT contrast agents was lower on conventional spin-echo (SE), Flash, and Turbo-Flash images than on EP images. The contrast agents exhibited higher SI on T2-weighted SE PE images and TI-time dependence on inversion recovery EP-images. The barium sulfate suspension was administered in volunteers to obtain information about bowel lumen enhancement and susceptibility artifacts. Oral administration of the aqueous barium sulfate suspension increased bowel lumen signal and reduced susceptibility artifacts. Approved aqueous gastrointestinal contrast media or flavored saline with long relaxation times may serve as safe, simple, and effective gastrointestinal contrast agents in abdominal EPI. Correspondence to: P. Reimer     

First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging

The authors report the results of preclinical testing and initial clinical application of a superparamagnetic iron oxide specifically prepared as a contrast agent for magnetic resonance (MR) imaging of the gastrointestinal tract. MR imaging was performed at 0.6 and 1.5 T in 15 volunteers. Images of the upper abdomen and pelvis were obtained before and after ingestion of the contrast material at doses of 22.5-225.0 mg of iron in 600-900 L. Two readers scored the images. Delivery of contrast material into the proximal and distal small bowel, with obvious loss of signal intensity (T2 enhancement), was achieved in all subjects. Enhanced images showed improved delineation of the head and tail of the pancreas, anterior margins of the kidneys, and paraaortic region. The contrast agent did not generate artifacts, an improvement over prototype formulations evaluated previously in animals. Except for a brief episode of diarrhea in five subjects, the agent was well tolerated. Use of this contrast agent improved the diagnostic quality of abdominal MR images by enabling the distinction of the bowel from nonbowel structures at concentrations that did not produce image distortion.     

Intraluminal contrast enhancement and MR visualization of the bowel wall: efficacy of PFOB.

Efforts to develop satisfactory intraluminal gastrointestinal contrast agents for magnetic resonance (MR) imaging have focused on depicting only the bowel lumen to exclude possible involvement by a pathologic process. To determine whether the bowel wall can be adequately imaged with use of the contrast agent and whether bowel wall visualization is a better index of the utility of the contrast agent for MR imaging, perfluoroocytlbromide (PFOB) was studied in human subjects. Twenty consecutive patients referred for abdominal or pelvic MR imaging were selected. All patients were given 400-1,000 mL of PFOB orally. MR imaging was performed at 0.38 and 1.5 T with T1- and T2-weighted spin-echo pulse sequences before and after administration of PFOB. The images were graded independently by three blinded readers. All readers reported significantly superior conspicuity of the bowel lumen and wall after PFOB than before PFOB administration (P less than .002). Among the post-PFOB studies, those with superior bowel wall visualization demonstrated superior overall image quality. In three patients, lesions were optimally demonstrated because the relationship of the process to the bowel wall, rather than just to the lumen, was identified. In two patients, masses arising within the bowel wall could be identified prospectively only when the bowel wall was adequately imaged. The authors conclude that while lumen identification is improved with PFOB, its greatest clinical utility may be in facilitating intestinal wall visualization.     

Oral superparamagnetic contrast agent (ferumoxsil): Tolerance and efficacy in MR imaging of gynecologic diseases

The purpose of this study was to determine the tolerance and the efficacy of the oral contrast agent ferumoxsil in the assessment of gynecologic diseases. Twenty patients underwent MR imaging at 1.5 T. T1-weighted spin-echo (SE) and T2-weighted fast SE images were obtained before and after ingestion of 600900 mL of the Superparamagnetic negative contrast agent ferumoxsil. No side effects were observed. No statistically significant increase in artifact generation was present in the postcontrast images. The efficacy in bowel marking was significant for the small bowel (P = 0.0001) and the cecum (P < 0.01), but not significant in all sequences for the sigmoid. In the postcontrast images, delineation of the uterus, the right-sided adnexa, the lymph nodes, and the pathologic lesions was significantly better (P < .01), but not all sequences showed an improvement in delineation of the other pelvic organs. After administration of ferumoxsil, the level of confidence in diagnosis was significantly higher (P = .0001), but no change in diagnosis was made from the preto the postcontrast images. We found the oral contrast agent ferumoxsil to be well tolerated and effective in marking the bowel and in delineating the normal organs as well as the pathologic lesions on pelvic MR images.     

Oral administration of a low-cost negative contrast agent: A three-year experience in routine practice

A low cost, well tolerated, and effective gastrointestinal contrast agent is needed for abdominal MRI. The authors tested, in vitro and in routine practice, a mixture of 192 g of barium sulfate (Micropaque HD oral, Guerbet, France) diluted in 500 ml of gastric antacid (Maalox, Rohrer, Fort Washington, PA). Its T1 and T2 relaxation times were 324 and 14 msec, respectively (.2 T). This contrast agent was used in routine practice in 789 patients (.5 T). It had a low signal intensity in 86% and 82% of the cases on T1- and T2-weighted sequences, respectively. No side effect due to magnetic susceptibility was seen, even with gradient-echo sequences. The dilution of barium sulfate in gastric ant-acid, instead of water, causes a low signal intensity on all sequences for a low barium sulfate concentration (38% w/v). This product is an effective and low cost contrast agent in routine practice.     

Blueberry juice used per os in upper abdominal MR imaging: composition and initial clinical data

The aim of this study was to evaluate the use of a commercially available blueberry juice (BJ) both as a positive and negative oral contrast agent and to present the exact contents of paramagnetic ions. The concentration of Mn and Fe were determined in tinned myrtilles in syrup (atomic absorption). Nine healthy volunteers and 12 patients (age range 20–65 years) were examined using a 1-T MR scanner before and after per os administration of 430 ml of BJ. A qualitative analysis of signal alterations in the stomach, duodenum, and proximal small intestine was performed. In addition, a quantitative analysis was assessed in terms of signal-to-noise ratio calculation. The mean concentration ( ×± SD) of the ions found in the content of the three cans were 3.3 ± 0.4 μg/g for iron and 20.6 ± 2.6 μg/g for manganese. Based on the qualitative evaluation, signal alteration on T1-weighted images after administration of BJ was statistically significant in the stomach and duodenum, but not in the proximal small bowel. Signal alteration on T2-weighted images was not statistically significant in any part of the gastrointestinal tract. The quantitative analysis of the T1- and T2 shortening showed that BJ is efficient with only T1-weighted sequences, and this applied to the stomach, duodenum, and proximal small bowel. Blueberry juice can be used as an oral contrast agent in upper abdominal MR for T1-weighted imaging. Received: 7 September 1999; Revised: 29 November 1999; Accepted: 16 February 2000     

Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon

The utility of perfluoroctylbromide (PFOB) as a gastrointestinal contrast agent for magnetic resonance (MR) imaging was evaluated with MR examinations performed in 30 subjects (16 healthy volunteers and 14 patients). Transaxial T1-, proton density-, and T2-weighted MR images were acquired in each subject before and after the administration of PFOB. The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration. The degree of bowel marking, clarity of bowel-wall visualization, ability to distinguish bowel from adjacent parenchymal organs, and severity of phase-encoding artifacts were independently analyzed by two reviewers. Oral administration of PFOB significantly (P less than .001) increased the percentage of bowel loops with low signal intensity. Subcutaneous administration of glucagon significantly (P less than .001) increased the clarity of bowel-wall visualization on post-PFOB MR studies. The severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.     

The role of MRI in the intestinal complications in cystic fibrosis.

Fibrosing colonopathy is a complication recently detected in children with cystic fibrosis (CF), and is thought to be associated with the use of high-strength pancreatic enzymes. The goal of this study was to evaluate the effectiveness of magnetic resonance (MR) in detecting possible pathologic gut findings in patients with CF under pancreatic enzyme treatment. Twenty-five patients with CF and pancreatic insufficiency, all under treatment with high-dose pancreatic enzymes, were studied by MR. MR was performed on a 1.5-T magnet by T1-weighted, 2D-FLASH fat-suppression, breath-hold sequences before and after intravenous administration of gadolinium, and by T2-weighted Turbo Spin-Echo (TSE) and Half-Fourier Acquisition Single-Shot Turbo Spin Echo (HASTE) fat-suppression, breath-hold sequences. A superparamagnetic negative oral contrast agent was given 1.5 h before the examination. MR showed a wall thickening of the terminal ileum and the ascending colon (>4-12 mm) in 22 patients; nine of them (wall thickness >4-6 mm) showed both a moderate hyperintensity of the bowel wall on T2-weighted sequences and an enhancement after intravenous gadolinium on T1-weighted sequences; 13 patients (wall thickness >6-12 mm) showed both a great wall enhancement after intravenous gadolinium and an increased signal intensity of the bowel wall on T2-weighted sequences. Fecal impaction without bowel wall involvement was detected in three patients. MR proved to be a useful, noninvasive, diagnostic tool for the evaluation of patients with CF and fibrosing colonopathy. The signal hyperintensity on T2-weighted sequences and the great wall enhancement after intravenous gadolinium administration indicating an acute edematous condition, provide the clinicians useful information for the therapeutic adjustment.     

Imaging of pancreatic neoplasms: comparison of MR and CT

Thirty-two patients with pathologically proved pancreatic carcinomas or cystadenomas were evaluated with MR images obtained with T1-weighted spin echo (short TR/short TE), inversion recovery, and T2-weighted spin-echo (long TR/long TE) pulse sequences. CT was used as the reference standard to determine the ability of MR to delineate normal and abnormal pancreatic anatomy and thereby to exclude or detect pancreatic malignancy. Short TR/short TE spin-echo sequences were significantly better (p less than .05) than inversion recovery or T2-weighted spin-echo sequences in resolution of both normal and abnormal anatomy. Resolution of pancreatic anatomy correlated (r = .9) with the image signal-to-noise ratio. In seven (22%) of 32 cases, MR visualized pancreatic tumors better than CT did because it showed a signal intensity difference between the tumor and normal pancreatic tissue. Overall, the slight superiority of MR over CT for tumor visualization tended to occur in larger tumors and was not statistically significant. On T1-weighted images, 63% (20 of 32) of pancreatic tumors studied had lower signal intensities than normal pancreatic tissue, whereas on T2-weighted sequences (TE = 60, 120, and 180 msec) only 41% (13 of 32) of tumors had increased signal intensities. Currently available MR imaging techniques offer no significant advantages over CT for evaluating the pancreas for neoplasia.     

MRI of pelvic masses: Efficacy of the rectal superparamagnetic contrast agent ferumoxsil

The purpose of this study was to determine the potential value of rectally administered Ferumoxsil for pelvic MRI. Twenty patients with suspected rectosigmoid and ovarian tumors were prospectively examined before and after rectal administration of 300 to 600 ml of the superparamagnetic contrast agent Ferumoxsil. Imaging parameters (1.5-T system, phased-array coil, transverse T1-weighted spin echo (SE) and T2-weighted turbo-SE sequences, 6-mm slice thickness, 350-mm field of view [FOV], 512 × 512 matrix) were kept constant. Images were evaluated for tumor presence, lymphadenopathy, bowel involvement, and peritoneal implants. Precontrast and postcontrast studies were rated for bowel delineation, lesion/organ-to-bowel differentiation, presence of artifacts, and confidence of diagnosis. Delineation of rectum and sigmoid colon (P < .001) as well as separation of bowel and vagina, uterus/adnexa, dome of the urinary bladder, lymph nodes, and vessels improved significantly (P < .01) on both T1-weighted and T2-weighted postcontrast sequences. The rectal contrast agent did not increase the level of artifacts. Changes in diagnosis in 7 of 20 patients were mainly due to identification of colorectal tumors or bowel involvement on postcontrast images. The readers' diagnostic confidence was significantly higher on contrast-enhanced than on unenhanced studies (93 ± 6.4% vs 68 ± 25.2%). Rectal application of Ferumoxsil improves lesion/organ-to-bowel delineation and overall diagnostic confidence in pelvic MRI.     

Ferric ammonium citrate as a positive bowel contrast agent for MR imaging of the upper abdomen. Safety and diagnostic efficacy.

PURPOSE: To evaluate the safety and diagnostic efficacy of two different doses of ferric ammonium citrate as a paramagnetic oral contrast agent for MR imaging of the upper abdomen. MATERIAL AND METHODS: Ninety-nine adult patients referred for MR imaging for a known or suspected upper abdominal pathology were included in this randomized multicenter double-blind clinical trial. Imaging was performed with spin-echo (T1- and T2-weighted) and gradient-echo (T1-weighted) techniques before and after administration of either 1200 mg or 2400 mg of ferric ammonium citrate dissolved in 600 ml of water. Safety analysis included monitoring of vital signs, assessment of adverse events, and laboratory testing. Efficacy with regard to organ distension, contrast distribution, bowel enhancement and delineation of adjacent structures was graded qualitatively. RESULTS: No serious adverse events were reported for either of the two concentrations. A total of 31 minor side effects were noted, of which significantly more occurred in the higher dose group (p<0.01). The diagnostic confidence in defining or excluding disease was graded as better after contrast administration for 48% of all images. Marked or moderate enhancement of the upper gastrointestinal tract was achieved at both doses in 69.5% of cases with no evident difference between the two doses. The higher dose tended to show better results in terms of the contrast assessment parameters. CONCLUSION: Ferric ammonium citrate is a safe and effective oral contrast agent for MR imaging of the upper abdomen at two different dose levels. The higher dose showed a tendency toward better imaging results while the lower dose caused significantly fewer side effects. Therefore the 1200 mg dose can be recommended in view of the risk-to-benefit ratio.     

MR colonography with barium-based fecal tagging: initial clinical experience

PURPOSE: To assess a strategy for fecal tagging with barium sulfate as an inexpensive tagging agent in conjunction with magnetic resonance (MR) colonography in patients suspected of having colorectal lesions. MATERIALS AND METHODS: Twenty-four patients suspected of having colonic lesions because of rectal bleeding, positive fecal occult blood test results, or altered bowel habits underwent MR colonography and subsequent conventional colonoscopy. A 200-mL dose of a barium sulfate-containing contrast agent was ingested with each of four low-fiber meals, beginning 36 hours before the examination. For MR colonography, the colon was filled with tap water. Gadobenate dimeglumine was injected intravenously. Images were acquired 75 seconds after gadobenate dimeglumine administration by using only a T1-weighted three-dimensional gradient-echo sequence. Images were reviewed by two radiologists blinded to conventional colonoscopic data. By using colonoscopy as the reference standard, sensitivity and specificity of MR colonography were determined for detecting colorectal masses. RESULTS: On the basis of MR colonography, 15 polyps of 5-20 mm and 10 carcinomas were detected and later confirmed with conventional colonoscopy. Conventional colonoscopy depicted three additional lesions less than 8 mm in diameter. Thus, sensitivity of MR colonography was 89.3% (25 of 28) for lesions and 91.7% (22 of 24) for patients. CONCLUSION: Barium-tagged MR colonography obviates bowel cleansing and depicts all lesions exceeding 8 mm in diameter.     

OMR, a positive bowel contrast agent for abdominal and pelvic MR imaging: safety and imaging characteristics.

To determine the safety and imaging characteristics of OMR--an effervescent solution of ferric ammonium citrate--as a bowel contrast agent, magnetic resonance (MR) imaging at 1.5 T was performed in 29 volunteers. T1- and T2-weighted images of the upper abdomen and pelvis were obtained before and after oral administration of OMR at doses of 100-400 mg of iron in 300-600 mL of water. Respiratory-ordered phase encoding and presaturation pulses were used routinely for artifact suppression. All dose levels of OMR provided marking of the bowel by increasing intraluminal signal intensity; however, the degree and percentage of small bowel opacification appeared more prominent at higher dose levels of iron. Semisolid or watery bowel movements were noted in 31% of subjects, but no clinically important laboratory abnormalities were seen. OMR improved delineation of the head of the pancreas on T1-weighted images in 72% of subjects but was less useful in defining the body and tail. OMR is a safe and effective bowel contrast agent for MR imaging. Because artifacts due to movement of hyperintense bowel may degrade the images, OMR may be most useful on short TR/TE or fast imaging pulse sequences or when combined with antiperistaltic agents.     

Intraluminal contrast agents for MR imaging of the abdomen and pelvis

Magnetic resonance (MR) imaging of the abdomen and pelvis with use of gastrointestinal (GI) contrast agents is slowly emerging as a valuable diagnostic tool. In the past few years, considerable effort has been expended on developing an oral contrast agent to serve as a bowel marker during abdominal and pelvic imaging. Four major categories of agents have been studied: compounds with positive contrast-enhancing characteristics (ie, which increase signal intensity), which may be either miscible or immiscible with bowel contents, and compounds with negative contrast-enhancing characteristics (ie, which decrease signal intensity), which also may be miscible or immiscible. Compared with precontrast images, MR images acquired after administration of GI contrast agents have shown increased anatomic delineation of the bowel lumen, pancreas, and paraaortic nodes, allowing increased detection of pancreatic lesions, improved assessment of bowel wall lesions, and distinction between intrahepatic and extrahepatic lesions. This review focuses on the general physics and requirements for intraluminal GI contrast media for MR imaging, the currently used intraluminal agents and their regulatory status, current and near-future availability, and cost considerations.     

The value of gadoterate meglumine as a gastrointestinal contrast agent in MRI

To evaluate the safety and efficacy of a gadoterate meglumine formulation as an oral contrast agent, MRI (0.5 T) was performed on 29 patients with abdominal disease before and after administration of contrast material. The patients ingested 16 ml/kg of a gadoterate meglumine solution (10 g/l glucose, 2 mmol/l gadoterate meglumine) over 1 h. Fourteen per cent of patients had mild side effects related to the contrast agent. Significant hyperintense contrast enhancement was achieved for the stomach and duodenum allowing better delineation of gastric and duodenal walls, entire pancreas and spleen on T1- and T2-weighted spin echo sequences. In 5 patients more diagnostic information was available from post-contrast images compared with precontrast images. This study shows that gadoterate meglumine is a safe and well-tolerated contrast agent that improves MRI of the proximal gastrointestinal tract and upper abdomen.Presented at the European Congress of Radiology, Vienna, Austria, 15–20 September 1991 Correspondence to: Y. Miaux